Background
Changing licensing and guidelines for Dolutegravir
Methods
Study design, number of children, randomisation and follow-up
Study population
Inclusion Criteria: | |
All | • Children ≥28 days and < 18 years weighing ≥3 kg with confirmed HIV-1 infectiona |
• Parents/carers and children, where applicable, give informed written consent | |
• Girls who have reached menses must have a negative pregnancy test at screening and randomisation and be willing to adhere to effective methods of contraception if sexually active | |
• Children with co-infections who need to start antiretroviral therapy can be enrolled according to local/national guidelines | |
• Parents/carers and children, where applicable, willing to adhere to a minimum of 96 weeks’ follow-up | |
ODYSSEY A (First-line) only | • Planning to start first-line antiretroviral therapy |
ODYSSEY B (Second-line) only | • Planning to start second-line antiretroviral therapy defined as either: (i) switch of at least 2 antiretroviral therapy drugs due to treatment failure; or (ii) switch of only the third agent due to treatment failure where drug sensitivity tests show no mutations conferring nucleos(t) ide reverse transcriptase inhibitors resistance |
• Treated with only one previous antiretroviral therapy regimen. Single drug substitutions for toxicity, simplification, changes in national guidelines or drug availability are allowed | |
• At least one nucleos(t) ide reverse transcriptase inhibitor with predicted preserved activity available for a background regimen | |
• In settings where resistance tests are routinely available, at least one active nucleos(t) ide reverse transcriptase inhibitor from TDF/TAF, ABC or ZDV should have preserved activity based on cumulative results of resistance tests | |
• In settings where resistance tests are not routinely available, children who are due to switch according to national guidelines should have at least one new nucleos(t) ide reverse transcriptase inhibitor predicted to be available from TDF/TAF, ABC or ZDV | |
• Viral load ≥500 c/ml at screening visit or within 4 weeks prior to screening‡ | |
Exclusion Criteria: | |
All | • History or presence of known allergy or contraindications to dolutegravir |
• History or presence of known allergy or contraindications to proposed available nucleos(t) ide reverse transcriptase inhibitor backbone or proposed available standard-of-care third agent. | |
• Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR ALT ≥3xULN and bilirubin ≥2xULN | |
• Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones) | |
• Anticipated need for Hepatitis C virus therapy during the study | |
• Pregnancy or breastfeeding | |
• Evidence of lack of susceptibility to integrase inhibitors or more than a 2-week exposure to antiretrovirals of this class |
Treatment of patients
WHO weight-band | FDA approvala | EMA approvalb | ODYSSEY v2.0a | ODYSSEY v3.0 | ODYSSEY v4.0 | ODYSSEY v5.0/v6.0 | ||
---|---|---|---|---|---|---|---|---|
(Sep 2016 onwards) | (Mar 2017 onwards) | (May 2018 onwards) | (May 2019/Feb 2020 onwards) | |||||
3 to < 6 kg | – | – | – | – | ||||
6 to < 10 kg | – | – | – | – | ||||
10 to < 14 kg | – | – | – | – | ||||
14 to < 20 kg | 20 mgc | Feb-2017 | 20 mg FCTd | 20 mg FCTd | 25 mg FCT → 25 mg DTf | 25 mg DT | ||
20 to <25 kg | 25 mg | Feb-2017 | 25 mg FCT | 25 mg FCT | 25 mg FCT → 30 mg DT or 50 mg FCTf | 50 mg FCT | ||
25 to < 30 kg | 25 mg | Feb-2017 | 25 mg FCT | 25 mg FCT → 50 mg FCTe | 25 mg FCT → 50 mg FCTe | 50 mg FCT | ||
30 to < 35 kg | 35 mg | Jun-2016 | 35 mg | Feb-2017 | 35 mg FCT | 35 mg FCT → 50 mg FCTe | 35 mg FCT → 50 mg FCTe | 50 mg FCT |
35 to < 40 kg | 35 mg | Jun-2016 | 35 mg | Feb-2017 | 35 mg FCT | 35 mg FCT → 50 mg FCTe | 35 mg FCT → 50 mg FCTe | 50 mg FCT |
≥40 kg | 50 mg | Aug-2013 | 50 mg | Jan-2014 | 50 mg FCT | 50 mg FCT | 50 mg FCT | 50 mg FCT |
Primary and secondary endpoints
Primary Efficacy Outcome | |
Difference in proportion with clinical or virological failure by 96 weeks, defined as the first occurrence of any of the following components: 1. Insufficient virological response defined as <1 log10 drop at week 24 (or viral load ≥50c/mL at week 24 in a participant with viral load < 500c/mL at baseline) and switch to second/third line antiretroviral therapy for treatment failure 2. Virological failure (defined as a viral load of greater than or equal to 400 copies/mL at or after week 36 confirmed by the next visit) 3. New or recurrent AIDS defining event (WHO 4) or severe WHO 3 event, confirmed by the Endpoint Review Committee (see Appendix) 4. All-cause death | |
Secondary efficacy outcomes | |
Difference in proportion with clinical or virological failure (as defined above) by 48 weeks | |
Time to any new or recurrent AIDS defining event (WHO 4) or severe WHO 3 events, confirmed by the Endpoint Review Committee | |
Proportion of children with Viral Load < 50 c/ml at 48 and 96 weeks | |
Proportion of children with Viral Load < 400 c/ml at 48 and 96 weeks | |
Rate of HIV-associated events (WHO 4 and severe WHO 3) and death over 96 weeks | |
Change in CD4 count and percentage and CD4/CD8 ratio from baseline to weeks 48 and 96 | |
Proportion developing new resistance mutations | |
Secondary safety outcomes | |
Change in total cholesterol, triglycerides and lipid fractions (high-density lipoproteins, low-density lipoproteins) from baseline to weeks 48 and 96 (change in total cholesterol from baseline to week 96 will be used to formally assess superiority of dolutegravir-based regimen vs. standard-of-care) | |
Incidence of serious adverse events | |
Incidence of new clinical and laboratory grade 3 and 4 adverse events | |
Incidence of adverse events (of any grade) leading to treatment modification | |
Other secondary outcomes | |
Quality of life | |
Adherence and acceptability |
Sample size calculations
Sub-studies
PK sub-studies
WHO weight-band | Initiated under Protocol v3.0 | Initiated under Protocol v4.0 |
---|---|---|
3 to < 6 kg | – | Single PK Curve on 5 mg or 10 mg DTa |
6 to < 10 kg | – | Single PK Curve on 15 mg DT |
10 to < 14 kg | – | Single PK Curve on 20 mg DT |
14 to < 20 kg | Single PK Curve on 25 mg FCT | Single PK Curve on 25 mg DTb |
20 to <25 kg | Single PK Curve on 25 mg FCT | Single PK Curve on 30 mg DT or 50 mg FCTb |
25 to < 30 kg | Cross-over PK with one curve on 25 mg FCT and second curve on 50 mg FCT | – |
30 to < 35 kg | Cross-over PK with one curve on 35 mg FCT and second curve on 50 mg FCT | – |
35 to < 40 kg | Cross-over PK with one curve on 35 mg FCT and second curve on 50 mg FCT | – |
≥40 kg | – | – |
Study procedures
Clinical Assessment | Frequency of Assessment |
---|---|
History and clinical assessment including height, weight (and adjustment of drug doses accordingly) and mid upper arm circumference, change in HIV disease stage, clinical events and presence of adverse events. | Every study visit |
Tanner scale (children aged 8 or over) | Baseline, then every 24 weeks and at the end of study visit |
Lipodystrophy assessment including at selected sites bioelectrical impedance analysis. | Baseline, then every 48 weeks and at the end of study visit |
HIV-1 RNA viral load | Every study visit as per local practice. In ODYSSEY B viral load must be measured at screening unless the viral load has been done within 4 weeks prior to screening. Stored plasma samples will be used to examined viral load for study visits where viral load is not routinely done. |
T cell lymphocyte subsets including CD4 and CD8 percentage and absolute, total lymphocyte count | Baseline, 4, 12, 24, then 24-weekly until week 96 and at the end of study visit |
Biochemistry including creatinine, bilirubin, alanine aminotransferase (ALT), and optionally aspartate aminotransferase (AST) | Baseline, 4, 24, then 24-weekly until week 96 and at the end of study visit |
Haematology including haemoglobin, mean corpuscular volume (MCV), white blood cell count, lymphocytes, neutrophils, and platelets | Baseline, 4, 24, then 24-weekly until week 96 and at the end of study visit |
Lipids/glucose including fasted triglycerides, cholesterol (total, high-density lipoproteins, low-density lipoproteins), and glucose | Baseline, 48, 96 weeks, then every 48 weeks and at the end of study visit |
Bone profile including calcium, phosphate, alkaline phosphatase | Optional for all sites at baseline, 48, 96 weeks, then every 48 weeks and at the end of study visit |
Urine dipstick for protein and glucose | Baseline, 48, 96 weeks then every 48 weeks and at the end of study visit |
Quality of Life questionnaire | Baseline, 12, 24, 48, 96 weeks then every 48 weeks and at the end of study visit |
Pregnancy test (for all females of childbearing potential) | This was originally at baseline and then every 24 weeks but following the pregnancy alert in DTG in May 2018 this was updated to every study visit (see Section entitled ‘Pregnancy Alert’) |
Plasma storage for retrospective HIV-1 RNA viral load, resistance testing where not routinely available locally and sub-study assays | Every visit |
Peripheral blood mononuclear cell storage at selected sites for immunology/virology sub-study | At selected sites for baseline, 12, 48, and 96 weeks |
Adherence questionnaire | Every visit |
Acceptability, sleep & mood questionnairea | Baseline, 4, 12, 24, 48, 72, 96 weeks, then every 24 weeks and at the end of study visit. Also acceptability should be completed if treatment failure has occurred or the antiretroviral therapy regimen changed. |
Study organisation, governance and ethics
Statistical analysis plan
Results
Challenges in study implementation- changing landscape of DTG dosing
Challenges in study implementation- pregnancy alert
-
Eligibility contingent on negative pregnancy test and adherence to effective methods of contraception (Table 1)
-
A pregnancy test every 24 weeks
-
Pregnancies in trial participants reported, and outcomes followed-up
-
Clinician discretion with respect to continuing DTG during pregnancy, with advice to consider alternative ART.
-
Participants were notified of this potential safety risk, prioritising those ≥15 years.
-
Patient information sheets and consent forms were updated
-
Availability of contraception and contraceptive counselling at each site was reviewed, and strengthened if necessary. Case report forms were revised to collect information about use of contraceptives.
-
Participants in the DTG arm who have a positive pregnancy test within 8 weeks of their last menstrual period or who wish to become pregnant are now advised to switch to a non-DTG ART regimen in consultation with their clinician.
-
The frequency of pregnancy testing for girls of childbearing age was increased to every (12-weekly) follow-up visit.
-
Collection of data on use of folate supplements (advised during pregnancy) was strengthened.
-
Youth Trial Board members created adolescent-friendly information on the safety alert, which can be provided to trial participants.
Post-trial access to DTG
Current status of the trial
ODYSSEY A | ODYSSEY B | Total | |||||
---|---|---|---|---|---|---|---|
(First-line) | (Second-line) | ||||||
Participants randomised ≥14 kg | 311 | 396 | 707 | ||||
Country/region | |||||||
Europe | 18 | (6%) | 7 | (2%) | 25 | (4%) | |
South Africa | 76 | (24%) | 67 | (17%) | 143 | (20%) | |
Thailand | 50 | (16%) | 11 | (3%) | 61 | (9%) | |
Uganda | 99 | (32%) | 232 | (59%) | 331 | (47%) | |
Zimbabwe | 68 | (22%) | 79 | (20%) | 147 | (21%) | |
Sex | |||||||
Male | 147 | (47%) | 215 | (54%) | 362 | (51%) | |
Female | 164 | (53%) | 181 | (46%) | 345 | (49%) | |
Age, years | |||||||
2 to < 6 | 12 | (4%) | 14 | (4%) | 26 | (4%) | |
6 to < 12 | 155 | (50%) | 161 | (41%) | 316 | (45%) | |
12 to < 18 | 144 | (46%) | 221 | (56%) | 365 | (52%) | |
Weight, kg | |||||||
14 to < 20 | 38 | (12%) | 44 | (11%) | 82 | (12%) | |
20 to < 25 | 62 | (20%) | 73 | (18%) | 135 | (19%) | |
25 to < 30 | 58 | (19%) | 59 | (15%) | 117 | (17%) | |
30 to < 35 | 33 | (11%) | 56 | (14%) | 89 | (13%) | |
35 to < 40 kg | 22 | (7%) | 39 | (10%) | 61 | (9%) | |
≥40 kg | 98 | (31%) | 125 | (32%) | 223 | (31%) | |
BMI-for-Age Z-Scorea | |||||||
<−3 | 12 | (4%) | 21 | (5%) | 33 | (5%) | |
−3 to < −2 | 24 | (8%) | 24 | (6%) | 48 | (7%) | |
−2 to < 0 | 178 | (57%) | 257 | (65%) | 435 | (62%) | |
≥0 | 97 | (31%) | 94 | (24%) | 191 | (27%) | |
Mode of infection | |||||||
Mother-to-child | 240 | (77%) | 365 | (92%) | 605 | (86%) | |
Blood product | 1 | (<1%) | 2 | (1%) | 3 | (<1%) | |
Sexual contact | 36 | (12%) | 3 | (1%) | 39 | (6%) | |
Unknown | 32 | (10%) | 26 | (7%) | 58 | (8%) | |
Otherd | 2 | (1%) | 0 | (0%) | 2 | (<1%) | |
CD4, cells/mm3b | |||||||
< 100 | 56 | (18%) | 54 | (14%) | 110 | (16%) | |
100 to < 200 | 20 | (6%) | 29 | (7%) | 49 | (7%) | |
200 to < 500 | 103 | (33%) | 128 | (32%) | 231 | (33%) | |
500 to < 1000 | 99 | (32%) | 130 | (33%) | 229 | (32%) | |
≥1000 | 33 | (11%) | 55 | (14%) | 88 | (13%) | |
CD4, % | |||||||
< 15 | 110 | (35%) | 119 | (30%) | 229 | (32%) | |
15 to < 25 | 100 | (32%) | 104 | (26%) | 204 | (29%) | |
≥25 | 101 | (32%) | 173 | (44%) | 274 | (39%) | |
Median CD4 (IQR), cells/mm3b | 436 | (210–660) | 482 | (243–752) | 459 | (228–704) | |
Viral load, copies/mLb | |||||||
< 1000 | 25 | (8%) | 6 | (2%) | 31 | (4%) | |
1000 to < 10,000 | 62 | (20%) | 122 | (31%) | 184 | (26%) | |
10,000 to < 50,000 | 76 | (24%) | 151 | (38%) | 227 | (32%) | |
50,000 to < 100,000 | 44 | (14%) | 44 | (11%) | 88 | (13%) | |
≥100,000 | 101 | (33%) | 73 | (18%) | 174 | (25%) | |
Median Log10 Viral load (IQR), copies/mLb | 4.6 | (3.9–5.1) | 4.3 | (3.8–4.8) | 4.4 | (3.9–5.0) | |
Clinical (WHO) Staging | |||||||
I | 127 | (41%) | 143 | (36%) | 270 | (38%) | |
II | 113 | (36%) | 135 | (34%) | 248 | (35%) | |
III | 47 | (15%) | 81 | (21%) | 128 | (18%) | |
IV | 23 | (8%) | 37 | (9%) | 60 | (8%) | |
Previous ART Class Exposurec | |||||||
NRTI/NNRTI | 382 | (96%) | |||||
NRTI/NNRTI/PIs | 4 | (1%) | |||||
NRTI/PIs | 10 | (3%) | |||||
Median cumulative ART exposure (IQR), yearsc | 5.5 | (3.5–8.1) |